This study was initiated three years ago by Children's Oncology Group as one of the first combined genomics and drug screen study to identify agents to try in a clinical trial. The study involved fourteen centers from all over the world and culminated in the identification of panobinostat as an effective agent. The data is especially useful because it constitutes a highly curated set of sequence data for in vivo model systems, as well as a large number of tissues for this rare cancer. The panobinostat treatment transcriptome data has the potential to reveal additional mechanisms for treating DIPG.